A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention

References

• . Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699
   PubMed Web of Science ®Google Scholar
• . The [UK] House of Commons: Select Committee on Health. Second Report. What is thromboembolism? ©Parlimentary copyright, 2005. Surrey, England, UK: The National Archives. http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/9906.htm#a5. Accessed February 9, 2011
   Google Scholar
• . Patel R, Cook DJ, Meade MO, . Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care. 2005;20(4):341–347
   PubMedGoogle Scholar
• . Kahn SR, Ducruet T, Lamping DL, . Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005;165(10):1173–1178
   PubMedGoogle Scholar
• . Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144–1148
   PubMedGoogle Scholar
• . Guyatt GH, Akl EA, Crowther M, ; American College of Chest Physicians. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( suppl 2):7S–47S
   PubMed Web of Science ®Google Scholar
• . Francis CW, Berkowitz SD, Comp PC, . Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703–1712
   PubMed Web of Science ®Google Scholar
• . El-Hadi W, Dorais M, Raymond V. Thromboprophylaxis patterns in patients undergoing elective total knee and hip replacement surgery in the province of Quebec [abstract]. J Popul Ther Clin Pharmacol. 2012;19(2):e142
   Google Scholar
• . Deitelzweig SB, McKean SC, Amin AN, Brotman DJ, Jaffer AK, Spyropoulos AC. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med. 2008;75( suppl 3):S27–S36
   Google Scholar
• . Rahme E, Dasgupta K, Burman M, . Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. [Erratum in CMAJ. 2008;179(1): 56]. CMAJ. 2008;178(12):1545–1554
   PubMed Web of Science ®Google Scholar
• . Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987;257(2):203–208
   PubMedGoogle Scholar
• . Bell GK, Goldhaber SZ. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Vase Med. 2001;6(1):23–29
   PubMedGoogle Scholar
• . Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995;155(7):757–764
   PubMedGoogle Scholar
• . Sullivan SD, Kahn SR, Davidson BL, Bonis L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003;21(7):477–496
   PubMedGoogle Scholar
• . O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ. 1994;150(7):1083–1090
   PubMed Web of Science ®Google Scholar
• . Hirsh J. Current anticoagulant therapy—unmet clinical needs. Thromb Res. 2003;109( suppl 1):S1–S8
   Web of Science ®Google Scholar
• . Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–2498
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010:375(9717):807–815
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604
   PubMed Web of Science ®Google Scholar
• . Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost. 2010;104(4):760–770
   PubMedGoogle Scholar
• . Canadian Institute for Health Information. Hip and Knee Replacements in Canada—Canadian Joint Replacement Registry. Canadian Joint Replacement Registry: 2008–2009 Annual Report. Ottawa, Ontario: CIHI; 2009
   Google Scholar
• . Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. Am J Cardiovasc Drugs. 2009;9(1):45–58
   PubMedGoogle Scholar
• . Collins S. Meta-analysis of apixaban and comparators for preventing venous thromboembolism in people undergoing elective knee and hip replacement surgery: NICE MTC analysis: Abacus International Pfi-SC-1810-2010/2073-2010;2010
   Google Scholar
• . Eriksson BI, Dahl OE, Rosencher N, ; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–956
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Dahl OE, Huo MH, . Dabigatran versus enoxaparin for thromboprophylaxis after primary hip arthroplasty: The RE-NOVATE II randomised trial. Presented at: 15th Congress of the European Haematology Association, June 10–13, 2010; Barcelona, Spain
   Google Scholar
• . Eriksson BI, Bonis LC, Friedman RJ, ; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Ageno W, Bonis LC, ; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786
   PubMed Web of Science ®Google Scholar
• . Kakkar AK, Brenner B, Dahl OE, ; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39
   PubMed Web of Science ®Google Scholar
• . Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. Postgrad Med. 2012;124(1):41–49
   PubMed Web of Science ®Google Scholar
• . Statistics Canada. Complete life tables Ontario, 2000–2002. http://www.statcan.gc.ca/. Accessed Februrary 9, 2011
   Google Scholar
• . Ontario Case Costing Initiative, http://www.occp.com/.2011. Accessed February 9, 2011
   Google Scholar
• . Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, www.healthinfo.moh.gov.on.ca/formulary/. Updated January 4, 2011. Accessed February 2011
   Google Scholar
• . Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoSMed. 2009;6(6):e1000098
   Google Scholar
• . New Brunswick Advisory Council on the Status of Women. Home Support Services: Cost and Effect, http://www.acswcccf.nb.ca/index.php?option=com_content&view=article&id=400&Itemid=58.2004. Accessed January 24, 2012
   Google Scholar
• . Sullivan PW. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43(7):736–749
   PubMed Web of Science ®Google Scholar
• . Sullivan PW. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the United States. Pharmacoeconomics. 2006;24(10):1021–1033
   PubMed Web of Science ®Google Scholar
• . Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health. 2006;9(2):68–76
   PubMedGoogle Scholar
• . Lenert LA. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4(1):49–56
   PubMed Web of Science ®Google Scholar